Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 23, 2025Anti-Cancer Drugs

Safety and efficacy of ivosidenib in the treatment of isocitrate dehydrogenase 1 mutant cholangiocarcinoma and acute myeloid leukemia: a systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

RQRameez QasimAllama Iqbal Medical CollegeLALaraib AnmolAllama Iqbal Medical CollegeISIzza ShakeelAllama Iqbal Medical College

Discussion

Loading...

Member takes

Implication

Systematic review reveals ivosidenib enhances progression-free survival and objective response rate in patients with IDH1 mutant cholangiocarcinoma and acute myeloid leukemia, suggesting its clinical use.

Key Points

  • Ivosidenib significantly improved the progression-free survival with a risk ratio of 0.79, indicating reduced tumor progression.
  • Objective response rate was enhanced with an odds ratio of 0.45, reflecting a substantial increase in treatment effectiveness.
  • A systematic review included four studies and analyzed data from 533 patients to evaluate the drug's impact.
  • While ivosidenib showed favorable outcomes in PFS and ORR, it did not significantly affect overall survival rates, indicating a selective therapeutic effect.

Cite This Study

Qasim et al. (2025) studied this question.

synapsesocial.com/papers/689a0621e6551bb0af8cddc1https://doi.org/10.1097/cad.0000000000001757
View Full Paper
Ask AI
Bookmark
Share